within Pharmacolibrary.Drugs.ATC.N;

model N02AB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.8333333333333334,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Ketobemidone is an opioid analgesic drug used mostly in Scandinavian countries for the management of moderate to severe pain. It acts as an agonist at the mu-opioid receptor and also exhibits NMDA antagonist properties. It is not approved for use in the United States or many other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li>James C Thigpen, Brian L Odle, Sam Harirforoosh,Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children.,European journal of drug metabolism and pharmacokinetics,2019<a href='https://pubmed.ncbi.nlm.nih.gov/31006834/'>https://pubmed.ncbi.nlm.nih.gov/31006834/</a></li><li>Ayman Al-Shurbaji, Juliette SÃ¤we,The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype.,European journal of clinical pharmacology,2002<a href='https://pubmed.ncbi.nlm.nih.gov/11936707/'>https://pubmed.ncbi.nlm.nih.gov/11936707/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02AB01;
